Latest Breaking News On - Charles weston - Page 1 : comparemela.com

Evotec SE (NASDAQ:EVO) Q1 2024 Earnings Call Transcript

Operator: Ladies and gentlemen, welcome to the Evotec SE Quarterly Statement Q1 2024 Conference Call. I am Sandra, the chorus call operator.

EVOTEC : Gets a Buy rating from RBC - MarketScreener

RBC analyst Charles Weston maintains his Buy rating on the stock. The target price is still set at EUR 16.

Uncertainty at Evotec hampers share price performance

Unclear prospects continue to dampen Evotec s share price on Wednesday after the latest figures. The pharmaceutical drug researcher and developer recorded a weaker start to the year, but above all the.

EVOTEC : RBC gives a Buy rating - MarketScreener

RBC analyst Charles Weston maintains his Buy rating on the stock. The target price is unchanged and still at EUR 16.

Oxford Biomedica : Preliminary Results of the year ended 31 December 2023 29 April 2024